Abstract
Diseases of the central nervous system are among the most devastating to patients and their families. Despite this, treatments for these diseases have lagged behind other therapeutic areas. Although social and economic factors may be partly responsible for the paucity of therapeutic agents, a particularly daunting challenge for CNS drug discovery is the need for compounds to cross the blood brain barrier. Recent analyses of successful drugs have shown that their chemical properties have not changed substantially over the past 40 years while the properties of compounds entering the clinic have become inflated. This property inflation has only exacerbated the challenges of CNS drug discovery as the requirements for delivery to the brain are even more stringent than those for other tissues. New approaches are needed to meet these challenges. In this review, we discuss the merits of fragment based lead discovery and how it may be used to address the challenges of CNS drug discovery. We also summarize compounds discovered by high-throughput screening, substrate evolution and fragment-based lead discovery for well known CNS targets. The results indicate that FBLD may be a key method for discovery of brain penetrable CNS therapeutics.
Keywords: Fragment-based lead discovery, blood brain barrier, central nervous system, Alzheimer's disease, schizophrenia, BACE, GSK3, PDE4
Current Topics in Medicinal Chemistry
Title: Start Small and Stay Small: Minimizing Attrition in the Clinic with a Focus on CNS Therapeutics
Volume: 9 Issue: 18
Author(s): Vicki Nienaber
Affiliation:
Keywords: Fragment-based lead discovery, blood brain barrier, central nervous system, Alzheimer's disease, schizophrenia, BACE, GSK3, PDE4
Abstract: Diseases of the central nervous system are among the most devastating to patients and their families. Despite this, treatments for these diseases have lagged behind other therapeutic areas. Although social and economic factors may be partly responsible for the paucity of therapeutic agents, a particularly daunting challenge for CNS drug discovery is the need for compounds to cross the blood brain barrier. Recent analyses of successful drugs have shown that their chemical properties have not changed substantially over the past 40 years while the properties of compounds entering the clinic have become inflated. This property inflation has only exacerbated the challenges of CNS drug discovery as the requirements for delivery to the brain are even more stringent than those for other tissues. New approaches are needed to meet these challenges. In this review, we discuss the merits of fragment based lead discovery and how it may be used to address the challenges of CNS drug discovery. We also summarize compounds discovered by high-throughput screening, substrate evolution and fragment-based lead discovery for well known CNS targets. The results indicate that FBLD may be a key method for discovery of brain penetrable CNS therapeutics.
Export Options
About this article
Cite this article as:
Nienaber Vicki, Start Small and Stay Small: Minimizing Attrition in the Clinic with a Focus on CNS Therapeutics, Current Topics in Medicinal Chemistry 2009; 9 (18) . https://dx.doi.org/10.2174/156802609790102374
DOI https://dx.doi.org/10.2174/156802609790102374 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments on the Studies of Human Memapsin 2 (β-Secretase)
Current Alzheimer Research A Co-Module Regulated by Therapeutic Drugs in a Molecular Subnetwork of Alzheimer’s Disease Identified on the Basis of Traditional Chinese Medicine and SAMP8 Mice
Current Alzheimer Research Highly Significant Scaffolds to Design and Synthesis Cholinesterase Inhibitors as Anti-Alzheimer Agents
Mini-Reviews in Medicinal Chemistry Tualang Honey and its Methanolic Fraction Improve LPS-induced Learning and Memory Impairment in Male Rats: Comparison with Memantine
Current Nutrition & Food Science Prevention of Cardiovascular Diseases with Anti-Inflammatory and Anti- Oxidant Nutraceuticals and Herbal Products: An Overview of Pre-Clinical and Clinical Studies
Recent Patents on Inflammation & Allergy Drug Discovery Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Reviews on Recent Clinical Trials Synthesis and In Vitro Evaluation of New Tacrine Derivates-Bis-Alkylene Linked 7-MEOTA
Letters in Organic Chemistry A Hyperlipidemic Diet Induces Structural Changes in Cerebral Blood Vessels
Current Neurovascular Research Association Constants of Pyridine and Piperidine Alkaloids to Amyloid ß Peptide Determined by Electrochemical Impedance Spectroscopy
Current Alzheimer Research Oleanolic Acid and Related Triterpenoids from Olives on Vascular Function: Molecular Mechanisms and Therapeutic Perspectives
Current Medicinal Chemistry The Forgotten Cells: Role of Astrocytes in Mood Disorders During the Aging
Current Neuropharmacology Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews The Association Between Diabetes and Cognitive Function in Later Life
Current Aging Science Activation and Control of CNS Innate Immune Responses in Health and Diseases: A Balancing Act Finely Tuned by Neuroimmune Regulators (NIReg)
CNS & Neurological Disorders - Drug Targets Role of Renin Angiotensin System Inhibitors in Cardiovascular and Renal Protection: A Lesson from Clinical Trials
Current Pharmaceutical Design Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Mass Spectrometric Analysis of F2-Isoprostanes: Markers and Mediators in Human Disease
Current Pharmaceutical Analysis AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Phosphodiesterase-4 Modulation as a Potential Therapeutic for Cognitive Loss in Pathological and Non-Pathological Aging: Possibilities and Pitfalls
Current Pharmaceutical Design A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design